Table 2.

Main and more severe adverse events during the neoadjuvant phase are shown.

Toxicity	VG (N = 39)	CG (N = 44)	p-value
All grades most common adverse events
Mucositis	39 (100)	28 (63.64)	0.004
Asthenia	31 (79.49)	25 (56.82)	0.052
Nausea and vomiting	30 (79.92)	22 (50.00)	0.009
Lymphopenia	14 (35.90)	17 (38.64)	0.751
Anemia	14 (35.90)	13 (29.54)	0.431
Diarrhea	10 (25.64)	6 (13.64)	0.055
Leucopenia	6 (15.38)	6 (13.64)	0.747
Neutropenia	5 (12.82)	8 (18.18)	0.336
Fever	5 (12.82)	7 (15.91)	0.564
Infection	4 (10.25)	6 (13.64)	0.488
Myalgia	4 (10.25)	1 (2.27)	0.02
Grade 3 or higher adverse events
Lymphopenia	8 (20.51)	9 (20.45)	0.992
Asthenia	6 (15.38)	6 (13.64)	0.747
Neutropenia	4 (10.25)	2 (4.55)	0.138
Leucopenia	2 (5.12)	2 (4.55)	0.908
Nausea and vomiting	–	5 (11.36)	<0.001
Mucositis	2 (5.12)	1 (2.27)	0.294
Myalgia	1 (2.56)	1 (2.27)	0.895
Anemia	–	1 (2.27)	0.132
Hypertransaminasemia	1 (2.56)	–	0.109

CG, control group; VG, vaccinated group.